Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.66 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906863 | 1.00 | HSD11B1 (0.66) | HSD11B1CYP11B1CYP11B2TRPV4 | |
| SCHEMBL2901552 | 0.87 | HSD11B1 (0.84) | HSD11B1 | |
| SCHEMBL2906875 | 0.87 | HSD11B1 (0.84) | HSD11B1 | |
| SCHEMBL2901556 | 0.87 | HSD11B1 (0.84) | HSD11B1 | |
| SCHEMBL2901341 | 0.82 | HSD11B1 (0.75) | HSD11B1 | |
| SCHEMBL2901346 | 0.82 | HSD11B1 (0.75) | HSD11B1 | |
| SCHEMBL2901680 | 0.73 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL2901682 | 0.73 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL2902116 | 0.73 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL2904737 | 0.69 | HSD11B1 (0.65) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735275-B1 | ARYL SULFONES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-18 | — | — | EP | claimed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | claimed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | ARSA, SULT2A1, UGT2B7 | HSD11B1 108/4885CYP11B1 32/4885CYP11B2 30/4885 |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885CYP11B1 17/4885CYP11B2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.